BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 32649013)

  • 21. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue.
    Nakada SY; di Sant'Agnese PA; Moynes RA; Hiipakka RA; Liao S; Cockett AT; Abrahamsson PA
    Cancer Res; 1993 May; 53(9):1967-70. PubMed ID: 8481896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.
    Nyquist MD; Corella A; Coleman I; De Sarkar N; Kaipainen A; Ha G; Gulati R; Ang L; Chatterjee P; Lucas J; Pritchard C; Risbridger G; Isaacs J; Montgomery B; Morrissey C; Corey E; Nelson PS
    Cell Rep; 2020 May; 31(8):107669. PubMed ID: 32460015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.
    Epstein JI; Amin MB; Beltran H; Lotan TL; Mosquera JM; Reuter VE; Robinson BD; Troncoso P; Rubin MA
    Am J Surg Pathol; 2014 Jun; 38(6):756-67. PubMed ID: 24705311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
    Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
    Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
    [No Abstract]   [Full Text] [Related]  

  • 25. Targeted Next-Generation Sequencing Reveals Heterogenous Genomic Features in Viscerally Metastatic Prostate Cancer.
    Gong Y; Fan L; Fei X; Zhu Y; Du X; He Y; Pan J; Dong B; Xue W
    J Urol; 2021 Aug; 206(2):279-288. PubMed ID: 33780283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
    Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
    Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential expression of αVβ3 and αVβ6 integrins in prostate cancer progression.
    Quaglia F; Krishn SR; Wang Y; Goodrich DW; McCue P; Kossenkov AV; Mandigo AC; Knudsen KE; Weinreb PH; Corey E; Kelly WK; Languino LR
    PLoS One; 2021; 16(1):e0244985. PubMed ID: 33481853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Role of neuroendocrine cells in prostate cancer progression].
    Sciarra A; Innocenzi M; Ravaziol M; Minisola F; Alfarone A; Cattarino S; Panebianco V; Buonocore V; Gentile V; Di Silverio F
    Urologia; 2011; 78(2):126-31. PubMed ID: 21574145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular events in neuroendocrine prostate cancer development.
    Wang Y; Wang Y; Ci X; Choi SYC; Crea F; Lin D; Wang Y
    Nat Rev Urol; 2021 Oct; 18(10):581-596. PubMed ID: 34290447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroendocrine cells of prostate cancer: biologic functions and molecular mechanisms.
    Huang YH; Zhang YQ; Huang JT
    Asian J Androl; 2019; 21(3):291-295. PubMed ID: 30924452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors.
    Qi J; Nakayama K; Cardiff RD; Borowsky AD; Kaul K; Williams R; Krajewski S; Mercola D; Carpenter PM; Bowtell D; Ronai ZA
    Cancer Cell; 2010 Jul; 18(1):23-38. PubMed ID: 20609350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation.
    Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Prostate; 2002 Mar; 50(4):203-15. PubMed ID: 11870798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
    Liu B; Li L; Yang G; Geng C; Luo Y; Wu W; Manyam GC; Korentzelos D; Park S; Tang Z; Wu C; Dong Z; Sigouros M; Sboner A; Beltran H; Chen Y; Corn PG; Tetzlaff MT; Troncoso P; Broom B; Thompson TC
    Clin Cancer Res; 2019 Nov; 25(22):6839-6851. PubMed ID: 31439587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PC3 is a cell line characteristic of prostatic small cell carcinoma.
    Tai S; Sun Y; Squires JM; Zhang H; Oh WK; Liang CZ; Huang J
    Prostate; 2011 Nov; 71(15):1668-79. PubMed ID: 21432867
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Blee AM; He Y; Yang Y; Ye Z; Yan Y; Pan Y; Ma T; Dugdale J; Kuehn E; Kohli M; Jimenez R; Chen Y; Xu W; Wang L; Huang H
    Clin Cancer Res; 2018 Sep; 24(18):4551-4565. PubMed ID: 29844131
    [No Abstract]   [Full Text] [Related]  

  • 36. MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.
    Bhagirath D; Liston M; Patel N; Akoto T; Lui B; Yang TL; To DM; Majid S; Dahiya R; Tabatabai ZL; Saini S
    Oncogene; 2020 Dec; 39(49):7209-7223. PubMed ID: 33037409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer.
    Gupta S; Halabi S; Kemeny G; Anand M; Giannakakou P; Nanus DM; George DJ; Gregory SG; Armstrong AJ
    Mol Cancer Res; 2021 Jun; 19(6):1040-1050. PubMed ID: 33771885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma.
    Alshalalfa M; Liu Y; Wyatt AW; Gibb EA; Tsai HK; Erho N; Lehrer J; Takhar M; Ramnarine VR; Collins CC; Den RB; Schaeffer EM; Davicioni E; Lotan TL; Bismar TA
    Int J Cancer; 2019 Dec; 145(12):3453-3461. PubMed ID: 31125117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity.
    Roudier MP; True LD; Vessella RL; Higano CS
    J Clin Pathol; 2004 Mar; 57(3):321-3. PubMed ID: 14990610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased nuclear factor I/B expression in prostate cancer correlates with AR expression.
    Nanda JS; Awadallah WN; Kohrt SE; Popovics P; Cates JMM; Mirosevich J; Clark PE; Giannico GA; Grabowska MM
    Prostate; 2020 Sep; 80(13):1058-1070. PubMed ID: 32692871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.